Elizabeth Homans - Sep 13, 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Executive Officer, Director
Signature
/s/ Heather Turner, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Sep 13, 2021
Transactions value $
$0
Form type
4
Date filed
9/14/2021, 04:17 PM
Previous filing
Jun 16, 2021
Next filing
Mar 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +1.37M $0.00 1.37M Sep 13, 2021 Common Stock 1.37M $16.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in equal monthly installments over the forty-eight months following September 13, 2021.